<DOC>
	<DOCNO>NCT01461616</DOCNO>
	<brief_summary>The objective describe interaction equal dose NPH insulin ( Neutral Protamine Hagedorn ) , insulin Detemir insulin glargine IGFBP-1 ( Insulin-like Growth Factor Binding Protein-1 ) production well immunoreactive bioactive IGF-I ( Insulin-like Growth Factor-I ) once-daily injection three separate visit type 1 diabetic subject .</brief_summary>
	<brief_title>Effect NPH Insulin , Insulin Detemir Insulin Glargine GH-IGF-IGFBP Axis</brief_title>
	<detailed_description>Because importance receptor activation potential effect IGF system , head-to-head comparison eventual differential impact intermediate-acting human insulin ( NPH ) , insulin detemir insulin glargine growth hormone—insulin-like growth factor—insulin-like growth factor bind protein ( GH-IGF-IGFBP ) axis relevant conduct safety assurance insulin analogue . Therefore , study aim investigate whether serum insulin profile obtain once-daily injection long-acting insulin analog , insulin detemir insulin glargine , different impact IGFBPs production IGF-I concentration ( total IGF-I ) bioactivity tissue-availability compare see treatment intermediate-acting human insulin , NPH insulin .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<criteria>1 . Informed consent obtain trialrelated activity . 2 . Diagnosis diabetes mellitus accord WHO criteria ; history clinical course consistent type 1 diabetes mellitus . 3 . Diagnosed diabetes 6 year use continuous subcutaneous insulin infusion ( CSII ) least 6 month time inclusion . 4 . Total daily insulin dose 0.4 1.4 units/kg ( value include ) 5 . HbA1c 6 % 9 % ( value include ) . 6 . Age ≥ 18 year . 7 . BMI 18.5 28 kg /m2 ( include value ) . 1 . Known suspect allergy trial product ( ) relate product . 2 . Recurrent major hypoglycaemic episode . 3 . Heart : Unstable Angina Pectoris , AMI &lt; 12 month heart insufficiency classify accord NYHA IIIIV 4 . Blood Pressure : Severe uncontrolled hypertension BP &gt; 180/110 mmHg , sit 5 . Liver : Impaired hepatic function correspond serumALAT basic phosphatase &gt; 2 x upper reference limit local laboratory . 6 . Kidneys : Impaired renal function correspond serumcreatinin &gt; 150 μmol/l accord local laboratory . 7 . Any disease judge investigator affect trial . 8 . Pregnancy , breastfeed intention become pregnant fertile woman use adequate contraceptive measure adequate contraceptive method sterilisation , hysterectomy current use contraceptive pill intra uterine device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Diabetes Mellitus , Type 1</keyword>
</DOC>